The present invention relates to apparatus and a method for the application of topical negative pressure (TNP) therapy to wounds. In particular, but not exclusively, the present invention relates to a method and apparatus for determining status such as a fullness associated with a canister in a TNP system.
There is much prior art available relating to the provision of apparatus and methods of use thereof for the application of TNP therapy to wounds together with other therapeutic processes intended to enhance the effects of the TNP therapy. Examples of such prior art include those listed and briefly described below.
TNP therapy assists in the closure and healing of wounds by reducing tissue oedema; encouraging blood flow and granulation of tissue; removing excess exudates and may reduce bacterial load and thus, infection to the wound. Furthermore, TNP therapy permits less outside disturbance of the wound and promotes more rapid healing.
In our co-pending International patent application, WO 2004/037334, apparatus, a wound dressing and a method for aspirating, irrigating and cleansing wounds are described. In very general terms, this invention describes the treatment of a wound by the application of topical negative pressure (TNP) therapy for aspirating the wound together with the further provision of additional fluid for irrigating and/or cleansing the wound, which fluid, comprising both wound exudates and irrigation fluid, is then drawn off by the aspiration means and circulated through means for separating the beneficial materials therein from deleterious materials. The materials which are beneficial to wound healing are recirculated through the wound dressing and those materials deleterious to wound healing are discarded to a waste collection bag or vessel.
In our co-pending International patent application, WO 2005/04670, apparatus, a wound dressing and a method for cleansing a wound using aspiration, irrigation and cleansing wounds are described. Again, in very general terms, the invention described in this document utilises similar apparatus to that in WO 2004/037334 with regard to the aspiration, irrigation and cleansing of the wound, however, it further includes the important additional step of providing heating means to control the temperature of that beneficial material being returned to the wound site/dressing so that it is at an optimum temperature, for example, to have the most efficacious therapeutic effect on the wound.
In our co-pending International patent application, WO 2005/105180, apparatus and a method for the aspiration, irrigation and/or cleansing of wounds are described. Again, in very general terms, this document describes similar apparatus to the two previously mentioned documents hereinabove but with the additional step of providing means for the supply and application of physiologically active agents to the wound site/dressing to promote wound healing.
The content of the above references is included herein by reference.
However, the above apparatus and methods are generally only applicable to a patient when hospitalised as the apparatus is complex, needing people having specialist knowledge in how to operate and maintain the apparatus, and also relatively heavy and bulky, not being adapted for easy mobility outside of a hospital environment by a patient, for example.
Some patients having relatively less severe wounds which do not require continuous hospitalisation, for example, but whom nevertheless would benefit from the prolonged application of TNP therapy, could be treated at home or at work subject to the availability of an easily portable and maintainable TNP therapy apparatus.
GB-A-2 307 180 describes a portable TNP therapy unit which may be carried by a patient clipped to belt or harness. It will however be appreciated that from time to time errors may occur during operation of the TNP therapy unit. One particular problem which can occur is that when a canister utilised to filter and store waste product becomes full correct operation of the TNP system can be impeded. With current devices two pressure sensors are required on each side of a canister to detect such an event. A change in measured pressure between the two sensors implies a blocked canister filter which further implies a full canister. It will be appreciated that the use of two such sensors is both expensive and prone to error and requires complex processing elements to determine when a canister is full.
It is an aim of the present invention to at least partly mitigate the above-mentioned problems.
It is an aim of embodiments of the present invention to provide a method and apparatus of determining status of a canister of a TNP system. More particularly, but not exclusively, it is an aim of embodiments of the present invention to provide a method and apparatus for determining when a canister of a TNP system is full.
It is an aim of embodiments of the present invention to provide an indication of when a canister of a TNP system is full without a requirement for two pressure sensors in the TNP system.
According to a first aspect of the present invention there is provided a method of determining status in a canister of a topical negative pressure (TNP) system, comprising the steps of:
The invention is comprised in part of an overall apparatus for the provision of TNP therapy to a patient in almost any environment. The apparatus is lightweight, may be mains or battery powered by a rechargeable battery pack contained within a device (henceforth, the term “device” is used to connote a unit which may contain all of the control, power supply, power supply recharging, electronic indicator means and means for initiating and sustaining aspiration functions to a wound and any further necessary functions of a similar nature). When outside the home, for example, the apparatus may provide for an extended period of operation on battery power and in the home, for example, the device may be connected to the mains by a charger unit whilst still being used and operated by the patient.
The overall apparatus of which the present invention is a part comprises: a dressing covering the wound and sealing at least an open end of an aspiration conduit to a cavity formed over the wound by the dressing; an aspiration tube comprising at least one lumen therethrough leading from the wound dressing to a waste material canister for collecting and holding wound exudates/waste material prior to disposal; and, a power, control and aspiration initiating and sustaining device associated with the waste canister.
The dressing covering the wound may be any type of dressing normally employed with TNP therapy and, in very general terms, may comprise, for example, a semi-permeable, flexible, self-adhesive drape material, as is known in the dressings art, to cover the wound and seal with surrounding sound tissue to create a sealed cavity or void over the wound. There may aptly be a porous barrier and support member in the cavity between the wound bed and the covering material to enable an even vacuum distribution to be achieved over the area of the wound. The porous barrier and support member being, for example, a foam or known wound contact type material resistant to crushing under the levels of vacuum created and which permits transfer of wound exudates across the wound area to the aspiration conduit sealed to the flexible cover drape over the wound.
The aspiration conduit may be a plain flexible tube, for example, having a single lumen therethrough and made from a plastics material compatible with raw tissue, for example. However, the aspiration conduit may have a plurality of lumens therethrough to achieve specific objectives relating to the invention. A portion of the tube sited within the sealed cavity over the wound may have a structure to enable continued aspiration and evacuation of wound exudates without becoming constricted or blocked even at the higher levels of the negative pressure range envisaged.
It is envisaged that the negative pressure range for the apparatus embodying the present invention may be between about −50 mmHg and −200 mmHg (note that these pressures are relative to normal ambient atmospheric pressure thus, −200 mmHg would be about 560 mmHg in practical terms). Aptly, the pressure range may be between about −75 mmHg and −150 mmHg. Alternatively a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also aptly a pressure range of below −75 mmHg could be used. Alternatively a pressure range of over −100 mmHg could be used or over −150 mmHg.
The aspiration conduit at its distal end remote from the dressing may be attached to the waste canister at an inlet port or connector. The device containing the means for initiating and sustaining aspiration of the wound/dressing may be situated between the dressing and waste canister, however, in a preferred embodiment of the apparatus embodying the present invention, the device may aspirate the wound/dressing via the canister thus, the waste canister may preferably be sited between the wound/dressing and device.
The aspiration conduit at the waste material canister end may preferably be bonded to the waste canister to prevent inadvertent detachment when being caught on an obstruction, for example.
The canister may be a plastics material moulding or a composite unit comprising a plurality of separate mouldings. The canister may aptly be translucent or transparent in order to visually determine the extent of filling with exudates. However, the canister and device may in some embodiments provide automatic warning of imminent canister full condition and may also provide means for cessation of aspiration when the canister reaches the full condition.
The canister may be provided with filters to prevent the exhaust of liquids and odours therefrom and also to prevent the expulsion of bacteria into the atmosphere. Such filters may comprise a plurality of filters in series. Examples of suitable filters may comprise hydrophobic filters of 0.2 μm pore size, for example, in respect of sealing the canister against bacteria expulsion and 1 μm against liquid expulsion.
Aptly, the filters may be sited at an upper portion of the waste canister in normal use, that is when the apparatus is being used or carried by a patient the filters are in an upper position and separated from the exudate liquid in the waste canister by gravity. Furthermore, such an orientation keeps the waste canister outlet or exhaust exit port remote from the exudate surface.
Aptly the waste canister may be filled with an absorbent gel such as ISOLYSEL (trade mark), for example, as an added safeguard against leakage of the canister when full and being changed and disposed of. Added advantages of a gel matrix within the exudate storing volume of the waste canister are that it prevents excessive movement, such as slopping, of the liquid, minimises bacterial growth and minimises odours.
The waste canister may also be provided with suitable means to prevent leakage thereof both when detached from the device unit and also when the aspiration conduit is detached from the wound site/dressing.
The canister may have suitable means to prevent emptying by a user (without tools or damage to the canister) such that a full or otherwise end-of-life canister may only be disposed of with waste fluid still contained.
The device and waste canister may have mutually complementary means for connecting a device unit to a waste canister whereby the aspiration means in the device unit automatically connects to an evacuation port on the waste canister such that there is a continuous aspiration path from the wound site/dressing to an exhaust port on the device.
Aptly, the exhaust port from the fluid path through the apparatus is provided with filter means to prevent offensive odours from being ejected into the atmosphere.
In general terms the device unit comprises an aspirant pump; means for monitoring pressure applied by the aspirant pump; a flowmeter to monitor fluid flow through the aspirant pump; a control system which controls the aspirant pump in response to signals from sensors such as the pressure monitoring means and the flowmeter, for example, and which control system also controls a power management system with regard to an on-board battery pack and the charging thereof and lastly a user interface system whereby various functions of the device such as pressure level set point, for example, may be adjusted (including stopping and starting of the apparatus) by a user. The device unit may contain all of the above features within a single unified casing.
In view of the fact that the device unit contains the majority of the intrinsic equipment cost therein ideally it will also be able to survive impact, tolerate cleaning in order to be reusable by other patients.
In terms of pressure capability the aspiration means may be able to apply a maximum pressure drop of at least −200 mmHg to a wound site/dressing. The apparatus is capable of maintaining a predetermined negative pressure even under conditions where there is a small leak of air into the system and a high exudate flow.
The pressure control system may prevent the minimum pressure achieved from exceeding for example −200 mmHg so as not to cause undue patient discomfort. The pressure required may be set by the user at a number of discreet levels such as −50, −75, −100, −125, −150, −175 mmHg, for example, depending upon the needs of the wound in question and the advice of a clinician. Thus suitable pressure ranges in use may be from −25 to −80 mmHg, or −50 to −76 mmHg, or −50 to −75 mmHg as examples. The control system may also advantageously be able to maintain the set pressure within a tolerance band of +/−10 mmHg of the set point for 95% of the time the apparatus is operating given that leakage and exudation rates are within expected or normal levels.
Aptly, the control system may trigger alarm means such as a flashing light, buzzer or any other suitable means when various abnormal conditions apply such as, for example: pressure outside set value by a large amount due to a gross leak of air into system; duty on the aspiration pump too high due to a relatively smaller leakage of air into the system; pressure differential between wound site and pump is too high due, for example, to a blockage or waste canister full.
The apparatus of the present invention may be provided with a carry case and suitable support means such as a shoulder strap or harness, for example. The carry case may be adapted to conform to the shape of the apparatus comprised in the joined together device and waste canister. In particular, the carry case may be provided with a bottom opening flap to permit the waste canister to be changed without complete removal of the apparatus from the carry case.
The carry case may be provided with an aperture covered by a displaceable flap to enable user access to a keypad for varying the therapy applied by the apparatus.
According to a second aspect of the present invention, there is provided apparatus for determining status in a canister of a topical negative pressure (TNP) system, comprising:
According to a third aspect of the present invention there is provided a method of determining the occurrence of a blockage of a canister filter in a topical negative pressure (TNP) system comprising the steps of:
According to a fourth aspect of the present invention there is provided apparatus for determining the occurrence of a blockage of a canister filter in a topical negative pressure (TNP) system, comprising:
Embodiments of the present invention provide a method and apparatus which allows the status of a canister of a topical negative pressure (TNP) system to be determined without the necessity to provide two pressure sensors in the TNP system. By monitoring the magnitude of pressure ‘pulses’ created by a pump possible leakage or the fact that a canister filter may be full can be detected. Optionally two or more sensors can be used if very prompt detection of errors is desired.
In order that the present invention may be more fully understood, examples will now be described by way of illustration only with reference to the accompanying drawings, of which:
Referring now to
More particularly, as shown in
According to embodiments of the present invention, actual pressure at a wound site is not measured but the difference between a measured pressure (at the pump) and the wound pressure is minimised by the use of large filters and large bore tubes wherever practical. If the pressure control measures that the pressure at the pump head is greater than a target pressure (closer to atmospheric pressure) for a period of time, the device sends an alarm and displays a message alerting the user to a potential problem such as a leak.
In addition to pressure control a separate flow control system can be provided. A flow meter may be positioned after the pump and is used to detect when a canister is full or the tube has become blocked. If the flow falls below a certain threshold, the device sounds an alarm and displays a message alerting a user to the potential blockage or full canister.
Referring now to
An aspirant pump 44 used to create the negative pressure of the TNP system is a diaphragm pump. This is utilised to move air and create the vacuum in the wound bed. The diaphragm acts as a miniature piston and, hence creates small pulses of pressure as it moves backwards and forwards. These pulses interfere with the flow of air through the system and their magnitude as measured, for example at the pump inlet, varies according to the status of the canister. This relationship is illustrated more clearly in
As shown in
Thus by measuring the magnitude of the pressure pulses it is possible to detect whether a canister is blocked.
It will also be appreciated that the frequency of pumping may also vary when a canister filter becomes full. The frequency can thus likewise additionally or optionally be utilised to determine status of at least one parameter such as fullness or leakiness associated with a canister of a TNP system.
Rather than initiating an alarm when the canister filter is full, the magnitude or frequency characteristics of the pressure can also be continually or periodically monitored with a magnitude being used to indicate current status. This can continually provide an indication such as percentage fullness which may be displayed via a user interface.
It will be appreciated that aptly the pressure is measured close to the location where the aspirant pump is provided in a TNP system. This is because damping effects caused by the volume of air in the flow path are minimised close to the pump inlet.
Embodiments of the present invention thus provide a manner in which the status of a canister such as a fullness of a filter associated with a canister can be determined by monitoring pressure provided by a pump of a TNP system. By determining a characteristic such as magnitude or frequency associated with the monitored pressure the status of at least one parameter such as fullness or a leak in a flow path associated with a canister can be determined. This can be achieved with only a single pressure sensor which obviates the need associated with prior known devices for two pressure sensors.
Embodiments of the present invention utilise a single pressure sensor downstream of a canister filter between a canister filter and a dressing of a TNP system to determine when a canister filter is full and needs replacing.
Embodiments of the present invention make use of two pressure sensors. One pressure sensor is located proximate to a pump inlet whilst a further pressure sensor is located downstream of a canister filter. This enable prompt detection of a leak and/or full canister filter.
Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, means “including but not limited to”, and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.
Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.
Number | Date | Country | Kind |
---|---|---|---|
0715259 | Aug 2007 | GB | national |
This application is a continuation of U.S. application Ser. No. 17/245,976, filed on Apr. 30, 2021, which is a continuation of U.S. application Ser. No. 16/845,348, filed on Apr. 10, 2020, now U.S. Pat. No. 10,994,060, issued on May 4, 2021, which is a continuation of U.S. application Ser. No. 15/851,020, filed on Dec. 21, 2017, now U.S. Pat. No. 10,617,801, issued on Apr. 14, 2020, which is a continuation of U.S. application Ser. No. 14/454,181, filed on Aug. 7, 2014, now U.S. Pat. No. 9,878,074, issued on Jan. 30, 2018, which is a continuation of U.S. application Ser. No. 12/672,468, filed on Feb. 5, 2010, now U.S. Pat. No. 8,843,327, issued on Sep. 23, 2014, which is a U.S. national stage application of International Patent Application No. PCT/GB2008/002346, filed Jul. 9, 2008, which claims priority to U.K. Patent Application No. 0715259.8, filed Aug. 6, 2007, which are hereby incorporated by reference in their entirety and made part of this disclosure.
Number | Name | Date | Kind |
---|---|---|---|
3568675 | Harvey | Mar 1971 | A |
3599639 | Spotz | Aug 1971 | A |
3882861 | Kettering et al. | May 1975 | A |
4080966 | Mcnally et al. | Mar 1978 | A |
4090966 | Clendenen | May 1978 | A |
4180074 | Murry et al. | Dec 1979 | A |
4291260 | Nixon | Sep 1981 | A |
4316466 | Babb | Feb 1982 | A |
4382441 | Svedman | May 1983 | A |
4468219 | George et al. | Aug 1984 | A |
4708010 | Sgourakes | Nov 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4795448 | Stacey et al. | Jan 1989 | A |
4930997 | Bennett | Jun 1990 | A |
4936832 | Vaillancourt | Jun 1990 | A |
4936834 | Beck et al. | Jun 1990 | A |
4957107 | Sipin | Sep 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4979944 | Luzsicza | Dec 1990 | A |
5002539 | Coble et al. | Mar 1991 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5356378 | Doan | Oct 1994 | A |
5419768 | Kayser | May 1995 | A |
5429601 | Conley et al. | Jul 1995 | A |
5449347 | Preen et al. | Sep 1995 | A |
5454700 | Iguchi et al. | Oct 1995 | A |
5549584 | Gross | Aug 1996 | A |
5549585 | Maher et al. | Aug 1996 | A |
5575762 | Peeler et al. | Nov 1996 | A |
5630855 | Lundb Ack | May 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5637093 | Hyman et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5690831 | Kenley et al. | Nov 1997 | A |
5744027 | Connell et al. | Apr 1998 | A |
5760754 | Amero, Jr. et al. | Jun 1998 | A |
5782608 | McKee | Jul 1998 | A |
5844137 | Carson | Dec 1998 | A |
5951502 | Peeler et al. | Sep 1999 | A |
5951863 | Kruger et al. | Sep 1999 | A |
5988842 | Johnsen et al. | Nov 1999 | A |
6053196 | Kortge | Apr 2000 | A |
6129440 | Reynolds | Oct 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
6142982 | Hunt et al. | Nov 2000 | A |
6159160 | Hsei et al. | Dec 2000 | A |
6229286 | Tokuyama | May 2001 | B1 |
6354805 | M.O Slashed.Ller | Mar 2002 | B1 |
6368311 | Valerio et al. | Apr 2002 | B1 |
6387086 | Mathias et al. | May 2002 | B2 |
6443983 | Nagyszalanczy et al. | Sep 2002 | B1 |
6458109 | Henley et al. | Oct 2002 | B1 |
6468042 | M.O Slashed.Ller | Oct 2002 | B2 |
6503219 | Milsom | Jan 2003 | B2 |
6558340 | Traeger | May 2003 | B1 |
6585675 | O'Mahony et al. | Jul 2003 | B1 |
6602468 | Patterson et al. | Aug 2003 | B2 |
6620379 | Piuk et al. | Sep 2003 | B1 |
6691047 | Fredericks | Feb 2004 | B1 |
6692132 | Meeker | Feb 2004 | B1 |
6695823 | Lina et al. | Feb 2004 | B1 |
6703807 | Sakata et al. | Mar 2004 | B2 |
6725731 | Wiklund et al. | Apr 2004 | B2 |
6755807 | Risk, Jr. et al. | Jun 2004 | B2 |
6764462 | Risk, Jr. et al. | Jul 2004 | B2 |
6786879 | Bolam et al. | Sep 2004 | B1 |
6814079 | Heaton et al. | Nov 2004 | B2 |
6824533 | Risk, Jr. et al. | Nov 2004 | B2 |
6855135 | Lockwood et al. | Feb 2005 | B2 |
6868739 | Krivitski et al. | Mar 2005 | B1 |
6916424 | Collins et al. | Jul 2005 | B2 |
6951553 | Bubb et al. | Oct 2005 | B2 |
7004915 | Boynton et al. | Feb 2006 | B2 |
7004923 | Deniega et al. | Feb 2006 | B2 |
7022113 | Lockwood et al. | Apr 2006 | B2 |
7042180 | Terry et al. | May 2006 | B2 |
7092797 | Gaines et al. | Aug 2006 | B2 |
7108683 | Zamierowski | Sep 2006 | B2 |
7128735 | Weston | Oct 2006 | B2 |
7160273 | Greter et al. | Jan 2007 | B2 |
7278981 | Ellingboe et al. | Oct 2007 | B2 |
7438705 | Karpowicz et al. | Oct 2008 | B2 |
7494482 | Orgill et al. | Feb 2009 | B2 |
7553306 | Hunt | Jun 2009 | B1 |
7611500 | Lina et al. | Nov 2009 | B1 |
7612247 | Oyaski | Nov 2009 | B2 |
7615158 | Sternby et al. | Nov 2009 | B2 |
7666171 | Mombrinie et al. | Feb 2010 | B2 |
7670323 | Hunt et al. | Mar 2010 | B2 |
7708724 | Weston | May 2010 | B2 |
7723560 | Lockwood et al. | May 2010 | B2 |
7744066 | Williams | Jun 2010 | B2 |
7744553 | Kelly et al. | Jun 2010 | B2 |
7753894 | Blott et al. | Jul 2010 | B2 |
7776001 | Brugger et al. | Aug 2010 | B2 |
7776028 | Miller et al. | Aug 2010 | B2 |
7790945 | Watson, Jr. | Sep 2010 | B1 |
7811269 | Boynton et al. | Oct 2010 | B2 |
7846141 | Weston | Dec 2010 | B2 |
7883494 | Martin | Feb 2011 | B2 |
7909805 | Weston | Mar 2011 | B2 |
7927319 | Lawhorn | Apr 2011 | B2 |
7998125 | Weston | Aug 2011 | B2 |
8062272 | Weston | Nov 2011 | B2 |
8100887 | Weston et al. | Jan 2012 | B2 |
8105295 | Blott et al. | Jan 2012 | B2 |
8162909 | Blott et al. | Apr 2012 | B2 |
8235939 | Johnson et al. | Aug 2012 | B2 |
8294586 | Pidgeon et al. | Oct 2012 | B2 |
8298200 | Vess et al. | Oct 2012 | B2 |
8308714 | Weston et al. | Nov 2012 | B2 |
8323264 | Weston et al. | Dec 2012 | B2 |
8333744 | Hartwell et al. | Dec 2012 | B2 |
8353857 | Rosenberg | Jan 2013 | B2 |
8377016 | Argenta et al. | Feb 2013 | B2 |
8444392 | Turner et al. | May 2013 | B2 |
8449487 | Hovland et al. | May 2013 | B2 |
8494349 | Gordon | Jul 2013 | B2 |
8529487 | Fava et al. | Sep 2013 | B2 |
8551061 | Hartwell | Oct 2013 | B2 |
8617129 | Hartwell | Dec 2013 | B2 |
8622981 | Hartwell et al. | Jan 2014 | B2 |
8663200 | Weston et al. | Mar 2014 | B2 |
8715256 | Greener | May 2014 | B2 |
8771259 | Karpowicz et al. | Jul 2014 | B2 |
8814841 | Hartwell | Aug 2014 | B2 |
8814842 | Coulthard et al. | Aug 2014 | B2 |
8834451 | Blott et al. | Sep 2014 | B2 |
8843327 | Vernon-Harcourt et al. | Sep 2014 | B2 |
8845603 | Middleton et al. | Sep 2014 | B2 |
8852149 | Weston et al. | Oct 2014 | B2 |
9199011 | Locke et al. | Dec 2015 | B2 |
9205183 | Hartwell et al. | Dec 2015 | B2 |
9227000 | Fink et al. | Jan 2016 | B2 |
9314557 | Ricci et al. | Apr 2016 | B2 |
9421309 | Robinson et al. | Aug 2016 | B2 |
9452244 | Blott et al. | Sep 2016 | B2 |
9878074 | Vernon-Harcourt et al. | Jan 2018 | B2 |
11559620 | Vernon-Harcourt | Jan 2023 | B2 |
20020156464 | Blischak et al. | Oct 2002 | A1 |
20020183702 | Henley et al. | Dec 2002 | A1 |
20020198503 | Risk, Jr. et al. | Dec 2002 | A1 |
20030014022 | Lockwood et al. | Jan 2003 | A1 |
20030040687 | Boynton et al. | Feb 2003 | A1 |
20030097100 | Watson | May 2003 | A1 |
20030235635 | Fong et al. | Dec 2003 | A1 |
20040260429 | Saelens | Dec 2004 | A1 |
20050067191 | Miyamoto et al. | Mar 2005 | A1 |
20060059980 | Matsubara et al. | Mar 2006 | A1 |
20060129137 | Lockwood et al. | Jun 2006 | A1 |
20060167607 | Nakamura et al. | Jul 2006 | A1 |
20060198503 | Wahl et al. | Sep 2006 | A1 |
20070014837 | Johnson et al. | Jan 2007 | A1 |
20070016152 | Karpowicz et al. | Jan 2007 | A1 |
20070032762 | Vogel | Feb 2007 | A1 |
20070032763 | Vogel | Feb 2007 | A1 |
20070118096 | Smith et al. | May 2007 | A1 |
20070129660 | McLeod et al. | Jun 2007 | A1 |
20070154319 | Stiles, Jr. et al. | Jul 2007 | A1 |
20070156104 | Lockwood et al. | Jul 2007 | A1 |
20070179460 | Adahan | Aug 2007 | A1 |
20070219532 | Karpowicz et al. | Sep 2007 | A1 |
20080071216 | Locke et al. | Mar 2008 | A1 |
20080071234 | Kelch et al. | Mar 2008 | A1 |
20080071235 | Locke | Mar 2008 | A1 |
20080139674 | Archambeau et al. | Jun 2008 | A1 |
20080200906 | Sanders et al. | Aug 2008 | A1 |
20080234641 | Locke et al. | Sep 2008 | A1 |
20080281281 | Meyer et al. | Nov 2008 | A1 |
20080300578 | Freedman | Dec 2008 | A1 |
20090012441 | Mulligan | Jan 2009 | A1 |
20090105670 | Bentley et al. | Apr 2009 | A1 |
20090163882 | Koch et al. | Jun 2009 | A1 |
20090299255 | Kazala, Jr. et al. | Dec 2009 | A1 |
20090299306 | Buan | Dec 2009 | A1 |
20090306630 | Locke et al. | Dec 2009 | A1 |
20100125259 | Olson | May 2010 | A1 |
20100174270 | Charlez et al. | Jul 2010 | A1 |
20100211030 | Turner et al. | Aug 2010 | A1 |
20100298792 | Weston et al. | Nov 2010 | A1 |
20100305490 | Coulthard et al. | Dec 2010 | A1 |
20110054810 | Turner et al. | Mar 2011 | A1 |
20110063117 | Turner et al. | Mar 2011 | A1 |
20110071483 | Gordon et al. | Mar 2011 | A1 |
20110077605 | Karpowicz et al. | Mar 2011 | A1 |
20110236460 | Stopek et al. | Sep 2011 | A1 |
20110251569 | Turner et al. | Oct 2011 | A1 |
20120001762 | Turner et al. | Jan 2012 | A1 |
20120111963 | Gordon et al. | May 2012 | A1 |
20130144227 | Locke et al. | Jun 2013 | A1 |
20130150813 | Gordon et al. | Jun 2013 | A1 |
20140163493 | Weston et al. | Jun 2014 | A1 |
20150025482 | Begin et al. | Jan 2015 | A1 |
Number | Date | Country |
---|---|---|
2349638 | May 2000 | CA |
1963258 | Jun 1971 | DE |
4016034 | Nov 1991 | DE |
19517699 | Nov 1996 | DE |
102005014420 | Sep 2006 | DE |
0194198 | Dec 1986 | EP |
0669463 | Aug 1995 | EP |
0853950 | Jul 1998 | EP |
0777504 | Oct 1998 | EP |
1393767 | Mar 2004 | EP |
1608032 | Dec 2005 | EP |
2066365 | Apr 2015 | EP |
1163907 | Oct 1958 | FR |
1334840 | Oct 1973 | GB |
2047438 | Nov 1980 | GB |
2235877 | Mar 1991 | GB |
2307180 | May 1997 | GB |
2336546 | Oct 1999 | GB |
2342584 | Apr 2000 | GB |
2356148 | May 2001 | GB |
2378734 | Feb 2003 | GB |
2418738 | Apr 2006 | GB |
WO-9605873 | Feb 1996 | WO |
WO-0017968 | Mar 2000 | WO |
WO-0061206 | Oct 2000 | WO |
WO-0105023 | Jan 2001 | WO |
WO-0172352 | Oct 2001 | WO |
WO-0219928 | Mar 2002 | WO |
WO-03022333 | Mar 2003 | WO |
WO-03030966 | Apr 2003 | WO |
WO-03053346 | Jul 2003 | WO |
WO-03101508 | Dec 2003 | WO |
WO-2005004670 | Jan 2005 | WO |
WO-2005006975 | Jan 2005 | WO |
WO-2005046760 | May 2005 | WO |
WO-2005105180 | Nov 2005 | WO |
WO-2005115497 | Dec 2005 | WO |
WO-2006052745 | May 2006 | WO |
WO-2006100053 | Sep 2006 | WO |
WO-2006105892 | Oct 2006 | WO |
WO-2006114638 | Nov 2006 | WO |
WO-2006135934 | Dec 2006 | WO |
WO-2007019038 | Feb 2007 | WO |
WO-2007030599 | Mar 2007 | WO |
WO-2007030601 | Mar 2007 | WO |
WO-2007070570 | Jun 2007 | WO |
WO-2007087808 | Aug 2007 | WO |
WO-2007087809 | Aug 2007 | WO |
WO-2007133618 | Nov 2007 | WO |
WO-2008010094 | Jan 2008 | WO |
WO-2008030872 | Mar 2008 | WO |
WO-2008036360 | Mar 2008 | WO |
WO-2008039314 | Apr 2008 | WO |
WO-2008048481 | Apr 2008 | WO |
WO-2008049029 | Apr 2008 | WO |
WO-2009019419 | Feb 2009 | WO |
WO-2009019495 | Feb 2009 | WO |
WO-2009019496 | Feb 2009 | WO |
WO-2009077722 | Jun 2009 | WO |
WO-2009089390 | Jul 2009 | WO |
Entry |
---|
Bagautdinov N.A., “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” in Current Problems in Modern Clinical Surgery, Interdepartmental Collection, 1986, pp. 94-96. |
Communication of the Registry - Opponents Reply to the Appeal for European Patent No. 2985044, dated Jan. 22, 2021, 25 pages. |
Decision revoking the European Patent for European Patent No. 2985044, mailed on Apr. 30, 2020, 28 pages. |
Extended European Search Report for Application No. 15183456.1, mailed on Dec. 23, 2015, 16 pages. |
Gambica, “Variable Speed Driven Pumps: Best Practice Guide,” British Pump Manufacturers Association, published online on Aug. 1, 2003, retrieved from http://www.gambica.org.uk/web_images/documents/publications/Gambica_VSD_Pumps_Best Practice_Guide.pdf, Mar. 22, 2013, 48 pages. |
Hicks T.G., “Mechanical Engineering Formulas Pocket Guide,” McGraw-Hill, Feb. 2003, 4 pages. |
Info V.A.C. User Manual, KCI on Dec. 1, 2006 in 76 pages. |
International Preliminary Report on Patentability for Application No. PCT/GB2008/002346, mailed on Feb. 9, 2010, 9 pages. |
International Search Report and Written Opinion for Application No. PCT/US2014/050233, mailed on Jan. 7, 2015, 16 pages. |
International Search Report for Application No. PCT/GB2008/002346, mailed on Oct. 27, 2008, 6 pages. |
International Search Report for Application No. PCT/GB2008/050507, mailed on Oct. 15, 2008, 5 pages. |
International Search Report for Application No. PCT/GB2008/050511, mailed on Oct. 31, 2008, 4 pages. |
International Search Report for Application No. PCT/GB2008/050515, mailed on Apr. 6, 2009, 6 pages. |
Invitation to Pay and Partial International Search Report for Application No. PCT/US2014/050233, mailed on Nov. 5, 2014, 8 pages. |
Jeter K F., et al., “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, Chapter 27, 1990, pp. 240-246. |
KCI, Inc., “Acti V.A.C. Therapy System,” User Manual, Sep. 2007, 64 pages. |
KCI, “V.A.C. User Manual,” The clinical advantage, 2003, 20 pages. |
Landis E.M., et al., “The Effects of Alternate Suction and Pressure on Blood Flow to the Lower Extremities,” Alternate Suction and Pressure, J Clin Invest, Sep. 1993, vol. 12 (5), pp. 925-961. |
Notice of Appeal on behalf of patentee for European patent No. 2985044 mailed on Jul. 9, 2020, 2 pages. |
Notice of Opposition—Statement of Facts and Evidence of the European Patent No. 2985044, dated Dec. 14, 2018, 22 pages. |
Nursing75., “Wound Suction: Better Drainage with Fewer Problems,” vol. 5(10), Oct. 1975, pp. 52-55. |
Office Action mailed Apr. 28, 2016 for Canadian Application No. 2695409, 3 pages. |
Office Action mailed Jun. 3, 2015 for Canadian Application No. 2695409, 3 pages. |
Opponent Arguments for European patent No. 2985044, mailed Jan. 3, 2020, 2 pages. |
Oral Proceedings of revocation for European Patent No. 2985044, dated Mar. 5, 2020, 9 pages. |
Patent Proprietor Arguments for European patent No. 2985044, mailed Jan. 3, 2020, 2 pages. |
Proprietor's statement of Grounds of Appeal for European Patent No. 2985044, dated Sep. 10, 2020, 7 pages. |
Provisional Non-Binding Opinion of the Opposition Division for European Patent No. 2985044, mailed Aug. 21, 2019, 7 pages. |
Reply of the Patent Proprietor to the Notice(s) of Opposition for European Patent No. 2985044, dated May 13, 2019, 13 pages. |
Sadasivan N., et al., “Studies on Frequency and Magnitude of Fluctuations of Pressure Drop in Gas-Solid Fluidised Beds,” Power Technology, vol. 26, May-Jun. 1980, 8 pages. |
US Medco Healthcare, “Healing through Technology,” HYPOwound Therapy System, Retrieved from http://www.usmedco.net on Apr. 18, 2006, 8 pages. |
Closure of the Appeal Proceedings for the Opposition of European Patent No. 2985044, dated Feb. 13, 2024, 1 page. |
Communication of the Board of Appeal pursuant to Article 15(1) for European Patent No. 2985044, mailed Nov. 9, 2023, 11 pages. |
Forwarding of submissions to parties of a letter of the opponent for European Patent No. 2985044, dated Jan. 8, 2024, mailed on Jan. 11, 2024, 6 pages. |
Forwarding of submissions to parties of a letter of the patent proprietor for European Patent No. 2985044, dated Dec. 10, 2023, mailed on Dec. 14, 2023, 14 pages. |
Minutes of the Oral Proceedings for the Opposition of European Patent No. 2985044, dated Feb. 6, 2024, 3 pages. |
Number | Date | Country | |
---|---|---|---|
20230226268 A1 | Jul 2023 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17245976 | Apr 2021 | US |
Child | 18099718 | US | |
Parent | 16845348 | Apr 2020 | US |
Child | 17245976 | US | |
Parent | 15851020 | Dec 2017 | US |
Child | 16845348 | US | |
Parent | 14454181 | Aug 2014 | US |
Child | 15851020 | US | |
Parent | 12672468 | US | |
Child | 14454181 | US |